Search results for "PSORIASIS"

showing 10 items of 193 documents

Tissue kallikrein and kininogen in human sweat glands and psoriatic skin

1991

The cellular localization of immunoreactive tissue kallikrein and kininogen was studied in normal and psoriatic human skin. Immunoreactivity to both enzyme and substrate was observed in secretory granules of the dark cells in the secretory fundus (acinus) of the sweat glands. Double immunostaining revealed a segmental distribution of the two antigens. Each acinar section contained either tissue kallikrein or kininogen. However, there appeared to be a junctional zone in which both were present, but in separate dark cells. Immunoreactivity for both antigens was also observed in close apposition to the luminal microvilli of the duct cells. No specific immunostaining was seen in sebaceous gland…

Kininogenmedicine.medical_specialtyPathologyStaining and LabelingKininogensTissue kallikreinMyoepithelial cellHuman skinDermatologyKallikreinBiologyKininImmunohistochemistrySweat GlandsEndocrinologymedicine.anatomical_structureSweat glandInternal medicinemedicineHumansPsoriasisKallikreinsCellular localizationSkincirculatory and respiratory physiologyBritish Journal of Dermatology
researchProduct

Langerinneg conventional dendritic cells produce IL-23 to drive psoriatic plaque formation in mice.

2013

Psoriasis is an autoinflammatory skin disease of unknown etiology. Topical application of Aldara cream containing the Toll-like receptor (TLR)7 agonist Imiquimod (IMQ) onto patients induces flares of psoriasis. Likewise, in mice IMQ triggers pathological changes closely resembling psoriatic plaque formation. Key cytokines like IL-23 and type-I IFN (IFN-I), both being produced mainly by dendritic cells (DCs), have been implicated in psoriasis. Although plasmacytoid DCs (pDCs) are the main source of IFNα and thought to initiate disease, conventional DCs (cDCs) appear to maintain the psoriatic lesions. Any role of cDCs during lesion formation remains elusive. Here, we report that selective ac…

LangerinCD11c610 Medicine & healthInflammation10263 Institute of Experimental ImmunologyInterleukin-23Mice03 medical and health sciences0302 clinical medicinePsoriasismedicineInterleukin 23AnimalsPsoriasisLectins C-Type030304 developmental biologyMice Knockout1000 Multidisciplinary0303 health sciencesImiquimodMembrane GlycoproteinsMultidisciplinarybiologyintegumentary systemhemic and immune systemsDendritic cellTLR7Biological SciencesAcquired immune systemmedicine.disease3. Good healthDisease Models AnimalMannose-Binding LectinsToll-Like Receptor 7Langerhans Cells030220 oncology & carcinogenesisAntigens SurfaceMyeloid Differentiation Factor 88ImmunologyAminoquinolinesbiology.protein570 Life sciences; biologymedicine.symptom
researchProduct

Visceral adiposity in patients with psoriatic arthritis and psoriasis alone and its relationship with metabolic and cardiovascular risk

2020

Abstract Background Fat mass distribution, especially in the abdominal visceral region, has been rarely evaluated in patients with PsA or psoriasis (PsO). Methods Patients with PsA and patients with PsO alone were evaluated and compared with control subjects (1:1 ratio in each patient group) matched for age, sex and BMI category. Body composition and fat distribution (android and visceral fat) were evaluated by DXA. Anthropometric measurements, disease activity and the systematic coronary risk evaluation (SCORE) cardiovascular risk were assessed. Metabolic parameters (insulin, homeostasis model assessment for insulin resistance), serum adipokines [total and high-molecular-weight adiponectin…

LeptinMalemedicine.medical_specialtyAdipokineIntra-Abdominal FatGastroenterologyBody Mass Index030207 dermatology & venereal diseases03 medical and health sciencesPsoriatic arthritisSex Factors0302 clinical medicineInsulin resistanceAdipokinesRheumatologyInternal medicinemedicineHumansInsulinPsoriasisResistinPharmacology (medical)030203 arthritis & rheumatologyAdiponectinbusiness.industryArthritis PsoriaticAge FactorsMiddle Agedmedicine.diseaseObesityHeart Disease Risk FactorsCase-Control StudiesObesity AbdominalMultivariate AnalysisBody CompositionFemaleResistinAndroid fat distributionInsulin ResistanceMetabolic syndromebusinessRetinol-Binding Proteins PlasmaRheumatology
researchProduct

Combination therapy of recalcitrant severe psoriasis with psoriatic arthritis, diabetes nephropathy, and liver cirrhosis

2021

Objective Treatment of recalcitrant moderate-to-severe psoriasis can be challenging. Combination therapy of biologics and immunosuppressive agents can be a new strategy for treating therapy-resistant cases with comorbidities, where many systemic medications are contraindicated. Case presentation We report a case of a 62-year-old diabetic man with a 30-year history of severe plaque psoriasis and psoriatic arthritis with cirrhosis and diabetic nephropathy that was treated successfully in combination with apremilast and etanercept after multiple previous unsuccessful treatment attempts. Conclusion There are no data supporting the combination of apremilast and etanercept in the management of re…

Liver CirrhosisMalemedicine.medical_specialtyCombination therapy610 MedizinDermatologyEtanerceptEtanerceptNephropathyDiabetic nephropathyPsoriatic arthritis610 Medical sciencesPsoriasisDiabetes MellitusmedicineHumansPsoriasisDiabetic Nephropathiesbusiness.industryArthritis PsoriaticMiddle Agedmedicine.diseaseDermatologyGuselkumabApremilastbusinessmedicine.drugJournal of Cosmetic Dermatology
researchProduct

Of men and mice: analysing the action of an established drug using tumour necrosis factor-α-deficient mice in the imiquimod psoriasis model

2016

Male0301 basic medicineDrugNecrosismedia_common.quotation_subjectImiquimodDermatologyPharmacologyMice030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicinePsoriasismedicineDeficient mouseAnimalsHumansPsoriasismedia_commonTumor Necrosis Factor-alphabusiness.industrymedicine.disease030104 developmental biologyAminoquinolinesmedicine.symptombusinessmedicine.drugBritish Journal of Dermatology
researchProduct

Incidence, Clinical Characteristics, and Management of Psoriasis Induced by Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: A Nationwid…

2016

Background: Psoriasis induced by anti-tumor necrosis factor-alpha (TNF) therapy has been described as a paradoxical side effect. Aim: To determine the incidence, clinical characteristics, and management of psoriasis induced by anti-TNF therapy in a large nationwide cohort of inflammatory bowel disease patients. Methods: Patients with inflammatory bowel disease were identified from the Spanish prospectively maintained Estudio Nacional en Enfermedad Inflamatoria Intestinal sobre Determinantes geneticos y Ambientales registry of Grupo Espanol de Trabajo en Enfermedad de Croh y Colitis Ulcerosa. Patients who developed psoriasis by anti-TNF drugs were the cases, whereas patients treated with ant…

MaleAnti-Inflammatory AgentsInflammatory bowel diseaseGastroenterologyCohort Studies030207 dermatology & venereal diseases0302 clinical medicineCrohn DiseaseadalimumabImmunology and AllergyIncidence (epidemiology)IncidenceGastroenterologypsoriasisPrognosisside effectsCrohn's diseaseCohort030211 gastroenterology & hepatologyTumor necrosis factor alphaFemaleCohort studyAdultmedicine.medical_specialtyAdolescent03 medical and health sciencesGastrointestinal Agentsinflammatory bowel diseasePsoriasisInternal medicinemedicineHumansPsoriasisColitisulcerative colitisbusiness.industryTumor Necrosis Factor-alphaCase-control studyAdalimumabanti-TNFmedicine.diseaseInfliximabWithholding TreatmentSpainCase-Control StudiesPhysical therapyColitis UlcerativebusinessinfliximabFollow-Up Studies
researchProduct

Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study

2019

Abstract Background Few data exist regarding the effectiveness of ustekinumab in inflammatory bowel disease (IBD) patients treated for concomitant psoriasis or psoriatic arthritis. Aims to describe the outcomes of IBD patients who received subcutaneous ustekinumab through a dermatological or rheumatological prescription. Methods This multicenter, retrospective study included all IBD patients who were started on ustekinumab for concomitant active psoriasis/ psoriatic arthritis, irrespective of IBD activity. The primary endpoint was overall ustekinumab persistence, defined as the maintenance of therapy because of sustained clinical benefit for IBD. Results Seventy patients (64 Crohn’s disease…

MaleCrohn’s diseaseSettore MED/16 - REUMATOLOGIAPsoriaticCrohn's disease; Psoriasis; Psoriatic arthritis; Ulcerative colitis; Ustekinumab; Hepatology; GastroenterologyInflammatory bowel disease0302 clinical medicineClinical endpointCrohn's disease Psoriasis Psoriatic arthritis Ulcerative colitis UstekinumabCrohn's diseaseSettore MED/12 - GastroenterologiaGastroenterologyMiddle AgedUlcerative colitisCrohn's diseaseTreatment OutcomeItaly030220 oncology & carcinogenesisPsoriatic arthritis030211 gastroenterology & hepatologyFemaleUstekinumabmedicine.drugAdultmedicine.medical_specialty03 medical and health sciencesPsoriatic arthritisCrohn's disease; Psoriasis; Psoriatic arthritis; Ulcerative colitis; Ustekinumab; Adult; Aged; Arthritis Psoriatic; Dermatologic Agents; Female; Humans; Inflammatory Bowel Diseases; Italy; Logistic Models; Male; Middle Aged; Psoriasis; Retrospective Studies; Treatment Outcome; Ustekinumab; Young AdultYoung AdultInternal medicinePsoriasisUstekinumabmedicineHumansPsoriasisAgedRetrospective StudiesHepatologybusiness.industryArthritisArthritis Psoriaticmedicine.diseaseInflammatory Bowel Diseasesdigestive system diseasesCrohn’s disease; Psoriasis; Psoriatic arthritis; Ulcerative colitis; UstekinumabLogistic ModelsUlcerative colitisConcomitantDermatologic Agentsbusiness
researchProduct

Pruritus characteristics in a large Italian cohort of psoriatic patients

2019

Background: Psoriasis (Ps) is a chronic systemic autoimmune disease associated with pruritus in 64–98% of patients. However, few modestly sized studies assess factors associated with psoriatic pruritus. Objective: To investigate factors associated with Ps pruritus intensity. Methods: Psoriasis patients 18 years or older seen in one of 155 centres in Italy between September 2005 and 2009 were identified from the Italian PsoCare registry. Patients without cutaneous psoriasis and those with missed information on pruritus were excluded. Results: We identified 10 802 patients, with a mean age 48.8 ± 14.3 years. Mild itch was present in 33.2% of patients, moderate in 34.4%, severe in 18.7% and ve…

MaleCross-sectional studySeverity of Illness IndexCohort Studies030207 dermatology & venereal diseases0302 clinical medicineRisk Factorseducation; itch; pruritus; psoriasis; pustular psoriasis; treatment; Adolescent; Adult; Cohort Studies; Cross-Sectional Studies; Educational Status; Facial Dermatoses; Female; Foot Dermatoses; Genitalia; Hand Dermatoses; Humans; Italy; Male; Middle Aged; Pruritus; Psoriasis; Registries; Risk Factors; Severity of Illness Index; Sex Factors; Young AdultEpidemiologyitchRegistriesYoung adultskin and connective tissue diseaseseducationtreatmentMiddle AgedSettore MED/33 - MALATTIE APPARATO LOCOMOTOREInfectious Diseasespustular psoriasisItaly030220 oncology & carcinogenesisCohortEducational StatusPRURITIS EPIDEMIOLOGYFemaleSettore MED/35 - MALATTIE CUTANEE E VENEREECohort studyAdultmedicine.medical_specialtyAdolescentPSORIASDermatologyHand DermatosesArticle03 medical and health sciencesYoung AdultPharmacotherapySex FactorsSettore MED/35PsoriasisSeverity of illnessmedicineHumansPsoriasisGenitaliaFoot Dermatosesbusiness.industryPruritusmedicine.diseaseDermatologyPruritusItch sensationCross-Sectional StudiesbusinessFacial Dermatoses
researchProduct

Psoriasis vulgaris and genetic markers

1977

In a sample of n = 160 nonrelated male and female patients suffering from psoriasis Vulgaris, blood serum protein, and enzyme group typings have been carried out and compared with healthy controls from the same area (Rheinland-Pfalz). Marked statistically significant differences between patients and controls were found in none of the genetic blood polymorphisms considered here. However, combining previously published data from various authors with our own, significant associations between this skin disease and genetic polymorphisms such as MN, Gc, Gm (2), red cell acid phosphatase, and red cell phosphoglucomutase (PGM1) were seen. The possible reasons for these associations are discussed.

MaleErythrocytesPolymorphism GeneticRed CellAcid PhosphataseBlood ProteinsBiologymedicine.diseaseMolecular medicineBlood proteinsPhosphoglucomutasePolymorphism (computer science)Genetic markerPsoriasisPGM1ImmunologyBlood Group AntigensGeneticsmedicineHumansMNSs Blood-Group SystemPsoriasisFemalePhosphoglucomutaseGenetics (clinical)Human Genetics
researchProduct

The GENDER ATTENTION Observational Study: Gender and Hormonal Status Differences in the Incidence of Adverse Events During Cyclosporine Treatment in …

2017

Introduction: Female sex has been shown to be a risk factor for the development of adverse drug reactions; however, this has not been studied for cyclosporine (CsA). The aim of this study was to investigate, in Italian dermatological practice, the influence of gender and menopause and related hormones on the incidence of adverse events (AEs) during CsA treatment in psoriatic patients. Methods: Multicenter, prospective, observational study conducted from May 2011 to June 2013. Patients with plaque psoriasis, undergoing a new CsA administration course, or about to start it, were enrolled in the outpatient clinics of Italian dermatological centers. During the 2–6 months of study duration, pati…

MaleSex FactorRate ratio030226 pharmacology & pharmacyGonadal Steroid HormoneSeverity of Illness Index0302 clinical medicineOutpatient clinicAdverse drug reaction; Cyclosporine; Dermatology; Female; Gender; PsoriasisPharmacology (medical)030212 general & internal medicineProspective StudiesProspective cohort studyGonadal Steroid HormonesOriginal ResearchIncidence (epidemiology)IncidenceMedicine (all)General MedicineMiddle AgedMenopausePostmenopauseItalyCyclosporineFemaleSettore MED/35 - MALATTIE CUTANEE E VENEREEHumanAdultmedicine.medical_specialtyAdolescentAdverse drug reaction; Cyclosporine; Dermatology; Female; Gender; Psoriasis; Adolescent; Adult; Cyclosporine; Female; Gonadal Steroid Hormones; Humans; Incidence; Italy; Male; Middle Aged; Postmenopause; Prospective Studies; Psoriasis; Severity of Illness Index; Sex Factors; Young Adult; Pharmacology (medical)Adverse drug reactionDermatology03 medical and health sciencesYoung AdultSex FactorsInternal medicineSeverity of illnessmedicineHumansPsoriasisRisk factorAdverse effectPsoriasibusiness.industryGendermedicine.diseaseSurgeryAdverse drug reaction; Cyclosporine; Dermatology; Female; Gender; Psoriasis; Medicine (all); Pharmacology (medical)Prospective StudiebusinessAdverse drug reaction; Cyclosporine; Dermatology; Female; Gender; Psoriasis;
researchProduct